VIDYASAGAR VANGALA: Open Payments
NPI 1679568133 · DAVENPORT, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$628 in 24 payments from 9 companies in 2025. Trend: 2023 $1,814 · 2024 $1,372 · 2025 $628
Food & beverage: $628
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $186 |
| Lundbeck LLC | 2 | $101 |
| Teva Pharmaceuticals USA, Inc. | 4 | $81 |
| Alkermes, Inc. | 3 | $67 |
| Neurocrine BioSciences, Inc. | 2 | $63 |
| Otsuka America Pharmaceutical, Inc. | 2 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Luye Pharma (USA) Ltd. | 1 | $20 |
Products named: CAPLYTA, REXULTI, AUSTEDO XR, INGREZZA, LYBALVI, TRINTELLIX, Auvelity, ARISTADA.
Industry payments across FL — which companies pay providers there.
